Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03435796 · ClinicalTrials.gov registry record · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Phase 2 study of Neoplasms, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,541
- Enrollment target
- 20
- Study locations
NCT03435796: Recruiting Phase 2 study of Neoplasms, sponsored by Celgene.
NCT03435796 is a Phase 2 study of Neoplasms that is actively recruiting participants, run by Celgene. The registered enrollment target is 1,541 participants, roughly in line with the 1,612-participant average among 158 other Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03435796, a Phase 2 study of Neoplasms, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,541 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Conditions Studied
Interventions
- GENETIC Gene-modified (GM) T cell therapy
Study Locations (20)
California
- City Of Hope - Duarte
- University Of California San Diego Moores Cancer Center - La Jolla
- Local Institution - 01206 - Los Angeles
- Local Institution - 01043 - Sacramento
- University of California, San Francisco- California - San Francisco
- UCLA Medical Centre-Santa Monica - Santa Monica
- Stanford Cancer Center - Stanford
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Phoenix - Phoenix
- Arizona Cancer Center - Scottsdale
- Local Institution - 01021 - Tucson
Florida
- The Mayo Clinic - Jacksonville, Davis-E - Jacksonville
- Baptist Cancer Center - Miami
- Local Institution - 01035 - Orlando
- H. Lee Moffitt Cancer Center and Research Institute University of South Florida - Tampa
Colorado
- University Of Colorado Cancer Center - Aurora
- Colorado Blood Cancer Institute - Denver
Alabama
- University of Alabama Birmingham - Birmingham
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Local Institution - 01050 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,541 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2036-11-30 |
| Phase | Phase 2 |
What NCT03435796 shows while recruiting
NCT03435796 is an interventional study that assigns participants to a tested intervention. Its 1,541 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,612-participant average among 158 other Neoplasms trials with a reported enrollment target.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Gene-modified (GM) T cell therapy is the first listed.
NCT03435796 names 20 study sites across 7 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03435796 about?
NCT03435796 is a clinical study titled "Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells". This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o...
What is the current status of trial NCT03435796?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,541 participants. The study started on 2018-07-19. Estimated completion is 2036-11-30.
What conditions does trial NCT03435796 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03435796?
The interventions under investigation include: Gene-modified (GM) T cell therapy (GENETIC).
Who is sponsoring clinical trial NCT03435796?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03435796 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03435796's enrollment target sits among peer trials
1,541 12th of 158 higher than 147 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
-
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI